Effects of Ticagrelor on No-reflow in Patients With Acute ST-segment Elevation Myocardial Infarction
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The 'no-reflow' phenomenon after a percutaneous coronary intervention (PCI) in patients with
acute ST-segment elevation myocardial infarction (STEMI) is a strong predictor of both short-
and long-term mortality. Faster antiplatelet activity and increased levels of adenosine
provide a theoretical basis for ticagrelor to effectively prevent no-reflow after PCI. We
planned to evaluate the effects of ticagrelor on myocardial no-reflow after PCI for STEMI.